Annals of the rheumatic diseases
-
To study the efficacy and safety of fasinumab in moderate-to-severe, chronic low back pain (CLBP). ⋯ Fasinumab highest doses, but not lower dose, improved both CLBP pain and function. Most joint AEs occurred in pOA patients, consistent with earlier findings in symptomatic OA. Further study is needed of patients with CLBP with and without pOA to determine optimal benefit-risk.
-
Observational Study
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. ⋯ Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.